Novo Nordisk submits obesity drug for FDA approval

Within the next six months, Novo Nordisk will find out whether its drug semaglutide can be used as a treatment for obesity, aside from its use as a drug against diabetes in US patients.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app